Effect of plasma lipids, hypertension and APOE genotype on cognitive decline

Neurobiology of Aging

Volumn 33, Issue 11, 2012, Pages 2633-2640

  Yasuno, Fumihiko ^a,b   Tanimukai, Satoshi ^a,c   Sasaki, Megumi ^a   Ikejima, Chiaki ^a   Yamashita, Fumio ^a,d   Kodama, Chiine ^a,d   Hidaka, Shin ^a   Mizukami, Katsuyoshi ^a   Asada, Takashi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

APOE genotype; Apolipoprotein E (APOE); Cognitive decline; High density lipoprotein (HDL); Hypertension; Low density lipoprotein (LDL); Total cholesterol (TC); Triglyceride (TG)

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AGED; ALLELE; APOLIPOPROTEIN E4 GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; COMMUNITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE; GENOTYPE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING; STRUCTURED INTERVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALLELES; APOLIPOPROTEINS E; COGNITION; COGNITION DISORDERS; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED;

EID: 84865578275     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.12.028     Document Type: Article

References (37)

1. Breteler M.M., van Swieten J.C., Bots M.L., Grobbee D.E., Claus J.J., van den Hout J.H., van Harskamp F., Tanghe H.L., de Jong P.T., van Gijn J., Hofman A. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994, 44:1246-1252.
2. Caselli R.J., Reiman E.M., Locke D.E., Hutton M.L., Hentz J.G., Hoffman-Snyder C., Woodruff B.K., Alexander G.E., Osborne D. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch. Neurol 2007, 64:1306-1311.
3. Cockerill G.W., Huehns T.Y., Weerasinghe A., Stocker C., Lerch P.G., Miller N.E., Haskard D.O. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001, 103:108-112.
4. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
5. Davignon J., Cohn J.S., Mabile L., Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin. Chim. Acta 1999, 286:115-143.
6. DeCarli C., Miller B.L., Swan G.E., Reed T., Wolf P.A., Garner J., Jack L., Carmelli D. Predictors of brain morphology for the men of the NHLBI twin study. Stroke 1999, 30:529-536.
7. Farkas E., Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol 2001, 2001:575-611.
8. Grober E., Buschke H., Crystal H., Bang S., Dresner R. Screening for dementia by memory testing. Neurology 1988, 38:900-903.
9. Han X. The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. Mol. Neurobiol 2010, 41:97-106.
10. Heeren J., Grewal T., Laatsch A., Becker N., Rinninger F., Rye K.A., Beisiegel U. Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J. Biol. Chem 2004, 279:55483-55492.
11. Heeren J., Grewal T., Laatsch A., Rottke D., Rinninger F., Enrich C., Beisiegel U. Recycling of apoprotein E is associated with cholesterol efflux and high density lipoprotein internalization. J. Biol. Chem 2003, 278:14370-14378.
12. Iurescia S., Fioretti D., Mangialasche F., Rinaldi M. The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches. J. Alzheimers Dis 2010, 21:35-48.
13. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 2000, 21:321-330.
14. Kester M.I., van der Flier W.M., Mandic G., Blankenstein M.A., Scheltens P., Muller M. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease. J. Alzheimers Dis 2010, 20:1083-1090.
15. Koudinov A.R., Berezov T.T., Kumar A., Koudinova N.V. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin. Chim. Acta 1998, 270:75-84.
16. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin. Chem. Lab. Med 2011, 49:375-383.
17. Masliah E., Mallory M., Ge N., Alford M., Veinbergs I., Roses A.D. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol 1995, 136:107-122.
18. Miyamoto M., Kodama C., Kinoshita T., Yamashita F., Hidaka S., Mizukami K., Kakuma T., Asada T. Dementia and mild cognitive impairment among non-responders to a community survey. J. Clin. Neurosci 2009, 16:270-276.
19. Olesen O.F., Dagø L. High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils. Biochem. Biophys. Res. Commun 2000, 270:62-66.
20. Pedersen W.A., Chan S.L., Mattson M.P. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J. Neurochem 2000, 74:1426-1433.
21. Peila R., White L.R., Petrovich H., Masaki K., Ross G.W., Havlik R.J., Launer L.J. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. Stroke 2001, 32:2882-2889.
22. Petrovitch H., White L.R., Izmirilian G., Ross G.W., Havlik R.J., Markesbery W., Nelson J., Davis D.G., Hardman J., Foley D.J., Launer L.J. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol. Aging 2000, 21:57-62.
23. Pfrieger F.W. Role of cholesterol in synapse formation and function. Biochim. Biophys. Acta 2003, 1610:271-280.
24. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993, 11:575-580.
25. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
26. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L.A., Nilsson L., Persson G., Odén A., Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347:1141-1145.
27. Small B.J., Rosnick C.B., Fratiglioni L., Bäckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 2004, 19:592-600.
28. Sohlberg M., Mateer C.A. Attention Process Training Manual 1986, Association for Neuropsychological Research and Development, Washington.
29. Solomon P.R., Pendlebury W.W. Recognition of Alzheimer's disease: the 7 Minute Screen. Fam. Med 1998, 30:265-271.
30. Sparks D.L., Scheff S.W., Liu H., Landers T.M., Coyne C.M., Hunsaker J.C. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J. Neurol. Sci 1995, 131:162-169.
31. Stratman N.C., Castle C.K., Taylor B.M., Epps D.E., Melchior G.W., Carter D.B. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem. Phys. Lipids 2005, 137:52-61.
32. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1977-1981.
33. Tangirala R.K., Praticó D., FitzGerald G.A., Chun S., Tsukamoto K., Maugeais C., Usher D.C., Puré E., Rader D.J. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J. Biol. Chem 2001, 276:261-266.
34. Wechsler D. WAIS-R: Manual: Wechsler Adult Intelligence Scale-Revised 1981, Harcourt Brace Jovanovich for Psychological Corp, New York.
35. Wenham P.R., Price W.H., Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991, 337:1158-1159.
36. Yasuno F., Tanimukai S., Sasaki M., Hidaka S., Ikejima C., Yamashita F., Kodama C., Mizukami K., Michikawa M., Asada T. Association between cognitive function and plasma lipids of the elderly after controlling for apolipoprotein E genotype. Am. J. Geriatr. Psychiatry 2011, 10.1097/JGP.0b013e318211819b.
37. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res 1982, 17:37-49.